dr. tefferi on the outlook for jak inhibitors in myelofibrosis
Published 10 years ago • 4.3K plays • Length 2:43Download video MP4
Download video MP3
Similar videos
-
5:34
treating with a jak inhibitor for myelofibrosis
-
1:54
dr. mesa discusses jak inhibitors for myelofibrosis
-
1:12
evidence supports rechallenging of jak inhibitors in myelofibrosis
-
25:13
update on jak inhibitors for myelofibrosis: there is more than one
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
1:47
dr. oh on the development of jak inhibitors in myelofibrosis
-
2:04
novel therapies for myelofibrosis patients who have failed jak inhibitors
-
2:42
the comfort-i and comfort-ii trials in myelofibrosis
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
1:08
dr. tefferi on the toxicity profile of imetelstat
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
19:04
my view on current and future use of jak inhibitors for et, pv, and mf
-
10:42
treatment of primary myelofibrosis
-
2:22
dr. mesa on the evolving role of jak2 inhibitors in myelofibrosis
-
2:34
dr. mesa on ruxolitinib in myelofibrosis
-
37:14
risk-adapted treatment in myelofibrosis: jak inhibitors and novel combination therapies
-
1:58
current research into jak inhibitors - specifially ruxolitinib, pacritinib, and momelotinib
-
0:58
dr. mesa on challenges with jak inhibitors in myelofibrosis